Free Research Reports on These Drug Delivery Stocks -- Bio-Path, IntelliPharmaCeutics, Adamis Pharma, and Alkermes

Wednesday, November 29, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 29, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information WallStEquities.com has issued free tailored Stock Review on BPTH, IPCI, ADMP, and ALKS which is a click away at www.wallstequities.com/registration. Featured today on WallStEquities.com are these four stocks in the Drug Delivery space:
Bio-Path Holdings Inc. (NASDAQ: BPTH), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), and Alkermes PLC (NASDAQ: ALKS). According to a new report by Visiongain, revenues of the world Drug Delivery Technology market will reach $198.4 billion in 2017. It also forecasts that the overall market for drug delivery technologies will grow steadily to 2023. An increasing focus on biologics and other innovative treatments in a wide range of therapeutic areas will drive the sector. Free Downloads on Wall St. Equities today, sign up now and access these stocks' research reports at: www.wallstequities.com/registration

Bio-Path Holdings

Bellaire, Texas-based Bio-Path Holdings Inc.'s stock finished Tuesday's session 1.41% higher at $0.28 with a total trading volume of 506,973 shares. Over the previous three months, the Company's shares have advanced 3.09%. The stock is trading below its 50-day moving average by 25.54%. Moreover, shares of Bio-Path, which operates as a clinical and preclinical stage oncology focused antisense drug development company in the US, have a Relative Strength Index (RSI) of 38.17.

On November 09th, 2017, Bio-Path announced its financial results for Q3 ended September 30th, 2017. Net loss attributable to common stockholders was $2.5 million; R&D expenses decreased to $1.6 million; and G&A expenses increased to $0.9 million. As of September 30th, 2017, the Company had cash of $4.6 million.

On November 13th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $4.50 a share to $1.50 a share. Free Access to this morning's research report on BPTH at: www.wallstequities.com/registration/?symbol=BPTH

IntelliPharmaCeutics International

Shares in Toronto, Canada-based IntelliPharmaCeutics International Inc. declined 1.33%, ending yesterday's session at $0.90 with a total trading volume of 89,541 shares. The stock is trading 7.60% below its 50-day moving average. Shares of the Company, which researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada, have an RSI of 44.74. Find your free research report IPCI at: www.wallstequities.com/registration/?symbol=IPCI

Adamis Pharmaceuticals

On Tuesday, San Diego, California headquartered Adamis Pharmaceuticals Corp.'s stock saw a decline of 5.00%, to close the day at $3.80. A total volume of 1.15 million shares was traded, which was above their three months average volume of 600,910 shares. The Company's shares have advanced 20.63% on an YTD basis. The stock is trading 17.42% below its 200-day moving average. Additionally, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 25.96. Sign up today for the free research report on ADMP at: www.wallstequities.com/registration/?symbol=ADMP

Alkermes

Shares in Dublin, Ireland headquartered Alkermes PLC ended the day 1.57% higher at $51.15. A total volume of 995,869 shares was traded, which was above their three months average volume of 860,330 shares. The stock has gained 2.61% in the last one month and 4.05% in the previous three months. The Company's shares are trading above their 50-day moving average by 1.91%. Furthermore, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 56.98.

On November 20th, 2017, Alkermes announced that it was named one of The Boston Globe's Top Places to Work. The Top Places to Work recognition applauds the most admired workplaces in the state based on anonymous employee feedback collected through a survey. The survey measures employee opinions about their company's direction, execution, connection, management, work, pay and benefits, and engagement. Wall St. Equities' research coverage also includes the downloadable free report on ALKS at: www.wallstequities.com/registration/?symbol=ALKS--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email inf[email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-drug-delivery-stocks----bio-path-intellipharmaceutics-adamis-pharma-and-alkermes-300563468.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store